Cargando…
BRAF vs RAS oncogenes: are mutations of the same pathway equal? differential signalling and therapeutic implications
As the increased knowledge of tumour heterogeneity and genetic alterations progresses, it exemplifies the need for further personalized medicine in modern cancer management. Here, the similarities but also the differential effects of RAS and BRAF oncogenic signalling are examined and further implica...
Autores principales: | Oikonomou, Eftychia, Koustas, Evangelos, Goulielmaki, Maria, Pintzas, Alexander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322985/ https://www.ncbi.nlm.nih.gov/pubmed/25361007 |
Ejemplares similares
-
BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells
por: Goulielmaki, Maria, et al.
Publicado: (2016) -
BRAF and RAS oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: a comparative study
por: Makrodouli, Eleni, et al.
Publicado: (2011) -
Selective BRAFV600E Inhibitor PLX4720, Requires TRAIL Assistance to Overcome Oncogenic PIK3CA Resistance
por: Oikonomou, Eftychia, et al.
Publicado: (2011) -
RAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally
por: Miller, Mark Steven, et al.
Publicado: (2012) -
The response to PAK1 inhibitor IPA3 distinguishes between cancer cells with mutations in BRAF and Ras oncogenes
por: Singhal, Ruchi, et al.
Publicado: (2012)